Superior Planning, LLC’s Travere Therapeutics TVTX Stock Holding History

Superior Planning, LLC’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$2.94K	Buy	+50	New	+$3.05K	﹤0.01%	1417

Other funds holding TVTX

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Stephens Investment Management Group Houston, Texas $9.29B AUM 41.16% 1-Year Est. Return

Emerald Advisers Leola, Pennsylvania $3.64B AUM 71.19% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

Renaissance Technologies New York $73.4B AUM 32.8% 1-Year Est. Return

Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return

Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.45B AUM 70.46% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $294B AUM 47.59% 1-Year Est. Return

Superior Planning, LLC's TVTX Position: Q3 2026 in Review

Superior Planning, LLC opened a new position in Travere Therapeutics (TVTX) in Q3 2026: 50 shares worth $2.94K. The stake represents ﹤0.01% of the portfolio and ranks #1417 among its holdings.

198 funds tracked by Wall St. Rank hold TVTX as of Q3 2026.

Superior Planning, LLC held 50 shares of Travere Therapeutics worth $2.94K as of Q3 2026.
Travere Therapeutics was a new Superior Planning, LLC position in Q3 2026.
Travere Therapeutics made up ﹤0.01% of Superior Planning, LLC's portfolio in Q3 2026, its #1417 holding.
198 funds tracked by Wall St. Rank held Travere Therapeutics as of Q3 2026.

Based on Superior Planning, LLC's 13F filing for Q3 2026, filed 12 Nov 2026.